{"commentary":{"count":25,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"x_thread":10,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05218499\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05218499","nct_id":"NCT05218499","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05218499. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) received 30 milligram (mg) brigimadlin taken orally on day 1 of each 21-day cycle (q3w).","label":"Brigimadlin 30 mg q3w","type":"EXPERIMENTAL"},{"description":"Patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) received 45 milligram (mg) brigimadlin taken orally on day 1 of each 21-day cycle (q3w).","label":"Brigimadlin 45 mg q3w","type":"EXPERIMENTAL"},{"description":"Patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) received one intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).","label":"Doxorubicin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-01-26","type":"ACTUAL"},"conditions":["Liposarcoma, Dedifferentiated"],"enrollment":{"count":400,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Brigimadlin","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"}],"last_update":"2026-03-02","lead_sponsor":"Boehringer Ingelheim","official_title":"Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2024-04-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to 20.6 months."}],"references":[{"citation":"Schoffski P, Lahmar M, Lucarelli A, Maki RG. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future Oncol. 2023 Mar;19(9):621-629. doi: 10.2217/fon-2022-1291. Epub 2023 Mar 29.","pmid":"36987836","type":"DERIVED"}],"start_date":{"date":"2022-03-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma","url":"https://clinicaltrials.gov/study/NCT05218499"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05218499"}